Dose adjustment of anaesthetics in the morbidly obese.

Anaesthesiologists must be prepared to deal with pharmacokinetic and pharmacodynamic (PD) differences in morbidly obese individuals. As drug administration based on total body weight can result in overdose, weight-based dosing scalars must be considered. Conversely, administration of drugs based on ideal body weight can result in a sub-therapeutic dose. Changes in cardiac output and alterations in body composition affect the distribution of numerous anaesthetic drugs. With the exception of neuromuscular antagonists, lean body weight is the optimal dosing scalar for most drugs used in anaesthesia including opioids and anaesthetic induction agents. The increased incidence of obstructive sleep apnoea and fat deposition in the pharynx and chest wall places the morbidly obese at increased risk for adverse respiratory events secondary to anaesthetic agents, thus altering the PD properties of these drugs. Awareness of the pharmacology of the commonly used anaesthetic agents including induction agents, opioids, inhalation agents and neuromuscular blockers is necessary for safe and effective care of morbidly obese patients.

[1]  S L Shafer,et al.  Pharmacokinetics, pharmacodynamics, and rational opioid selection. , 1991, Anesthesiology.

[2]  P. Toft,et al.  Anthropometric Variables as Predictors for Duration of Action of Vecuronium‐Induced Neuromuscular Block , 1994, Anesthesia and analgesia.

[3]  D. McClain,et al.  Intravenous fentanyl kinetics , 1980, Clinical pharmacology and therapeutics.

[4]  I. Mahmood Prediction of Drug Clearance in Children: Impact of Allometric Exponents, Body Weight, and Age , 2007, Therapeutic drug monitoring.

[5]  R. Emilia,et al.  Faster wash-out and recovery for desflurane vs sevoflurane in morbidly obese patients when no premedication is used. , 2007, British journal of anaesthesia.

[6]  M. Struys,et al.  Pharmacokinetic models for propofol--defining and illuminating the devil in the detail. , 2009, British journal of anaesthesia.

[7]  I. Fermo,et al.  No adjustment vs. adjustment formula as input weight for propofol target-controlled infusion in morbidly obese patients , 2009, European journal of anaesthesiology.

[8]  S. Zanotti-Cavazzoni Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial , 2010 .

[9]  D. Abernethy,et al.  Pediatric Dose Selection , 2010, Clinical pharmacology and therapeutics.

[10]  I. Mahmood Prediction of Clearance, Volume of Distribution and Half‐life by Allometric Scaling and by use of Plasma Concentrations Predicted from Pharmacokinetic Constants: a Comparative Study , 1999, The Journal of pharmacy and pharmacology.

[11]  Pancuronium bromide requirement during anesthesia for the morbidly obese. , 1979, Anesthesiology.

[12]  S. Harapat,et al.  Computer Simulation of the Effects of Alterations in Blood Flows and Body Composition on Thiopental Pharmacokinetics in Humans , 1997, Anesthesiology.

[13]  N. Morton,et al.  Pharmacokinetic model driven infusion of propofol in children. , 1991, British journal of anaesthesia.

[14]  P. White,et al.  Dexmedetomidine Infusion During Laparoscopic Bariatric Surgery: The Effect on Recovery Outcome Variables , 2008, Anesthesia and analgesia.

[15]  L. Colla,et al.  Predictive Performance of the ‘Minto’ Remifentanil Pharmacokinetic Parameter Set in Morbidly Obese Patients Ensuing from a New Method for Calculating Lean Body Mass , 2010, Clinical pharmacokinetics.

[16]  G. Drummond Comparison of decreases in ventilation caused by enflurane and fentanyl during anaesthesia. , 1983, British journal of anaesthesia.

[17]  E. Eger,et al.  Obesity Modestly Affects Inhaled Anesthetic Kinetics in Humans , 2008, Anesthesia and analgesia.

[18]  D. Salazar,et al.  Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. , 1988, The American journal of medicine.

[19]  H. T. Lee The Dose of Succinylcholine in Morbid Obesity , 2007 .

[20]  D. Morgan,et al.  Lean Body Mass as a Predictor of Drug Dosage , 1994, Clinical pharmacokinetics.

[21]  C. Bailey Long-Duration Low-Flow Sevoflurane and Isoflurane Effects on Postoperative Renal and Hepatic Function , 2002 .

[22]  M. Inchiosa,et al.  Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. , 2005, British journal of anaesthesia.

[23]  D. Ray,et al.  Induction drug and outcome of patients admitted to the intensive care unit after emergency laparotomy , 2010, European journal of anaesthesiology.

[24]  G. Forbes,et al.  Lean body mass in obesity. , 1983, International journal of obesity.

[25]  R. Matteo,et al.  Pharmacodynamics of Vecuronium and Atracurium in the Obese Surgical Patient , 1988, Anesthesia and analgesia.

[26]  M. Struys,et al.  Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. , 2010, British journal of anaesthesia.

[27]  G. Cheymol Effects of Obesity on Pharmacokinetics , 2000 .

[28]  W. Young,et al.  Pharmacokinetics of Sufentanil in Obese Patients , 1991, Anesthesia and analgesia.

[29]  Johann Greilhuber,et al.  Intraspecific Variation in Genome Size: A Critical Reassessment , 1998 .

[30]  M. Pai,et al.  The Origin of the “Ideal” Body Weight Equations , 2000, The Annals of pharmacotherapy.

[31]  R. Shankar,et al.  Obesity, obstructive sleep apnoea, and diabetes mellitus: anaesthetic implications. , 2009, British journal of anaesthesia.

[32]  Stephen B. Duffull,et al.  Quantification of Lean Bodyweight , 2005, Clinical pharmacokinetics.

[33]  K. Tsueda,et al.  Pancuronium Bromide Requirement during Anesthesia for the Morbidly Obese , 1978 .

[34]  J. Brodsky,et al.  Lean Body Weight Scalar for the Anesthetic Induction Dose of Propofol in Morbidly Obese Subjects , 2011, Anesthesia and analgesia.

[35]  R N Upton,et al.  Cardiac output is a determinant of the initial concentrations of propofol after short-infusion administration. , 1999, Anesthesia and analgesia.

[36]  D. Perrier,et al.  Thiopental Disposition in Lean and Obese Patients Undergoing Surgery , 1982, Anesthesiology.

[37]  Thomas W. Schnider,et al.  Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development , 1997 .

[38]  B. Murray When does intraspecific C-value variation become taxonomically significant? , 2005, Annals of botany.

[39]  Edward J Boyko,et al.  Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution. , 2009, The Journal of clinical endocrinology and metabolism.

[40]  J. P. Adams,et al.  Obesity in anaesthesia and intensive care. , 2000, British journal of anaesthesia.

[41]  M. Bird Acute Pain Management: A New Area of Liability for Anesthesiologists , 2007 .

[42]  J. Benumof Obesity, sleep apnea, the airway and anesthesia , 2004, Current opinion in anaesthesiology.

[43]  G. Lesser,et al.  Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr. , 1967, Journal of applied physiology.

[44]  R. Matteo,et al.  Pharmacokinetics and Pharmacodynamics of Vecuronium in the Obese Surgical Patient , 1992, Anesthesia and analgesia.

[45]  E. Bignami,et al.  Wash-in and wash-out curves of sevoflurane and isoflurane in morbidly obese patients. , 2002, Minerva anestesiologica.

[46]  J. Brodsky,et al.  Perioperative management of the obese patient. , 1993, British journal of anaesthesia.

[47]  Talmage D. Egan,et al.  Remifentanil Pharmacokinetics in Obese versus Lean Patients , 1998, Anesthesiology.

[48]  A. Benzer,et al.  Pharmacokinetics of Rocuronium Bromide in Obese Female Patients , 2000 .

[49]  S. Shafer,et al.  The Influence of Method of Administration and Covariates on the Pharmacokinetics of Propofol in Adult Volunteers , 1998, Anesthesiology.

[50]  K. Stokholm,et al.  Increased glomerular filtration rate and adrenocortical function in obese women. , 1980, International journal of obesity.

[51]  AT Murugan,et al.  Obesity and respiratory diseases , 2008, Chronic respiratory disease.

[52]  James C. Scott,et al.  Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. , 1990, Anesthesiology.

[53]  E. Bulger,et al.  Single-dose etomidate for rapid sequence intubation may impact outcome after severe injury. , 2009, The Journal of trauma.

[54]  Darrell R. Abernethy,et al.  Effect of Obesity on the Pharmacokinetics of Drugs in Humans , 2010, Clinical pharmacokinetics.

[55]  P. Kam,et al.  Obesity: basic science and medical aspects relevant to anaesthetists , 2005, Anaesthesia.

[56]  W. Hoffman,et al.  Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery. , 2006, Journal of clinical anesthesia.

[57]  S. Duffull,et al.  What is the best size descriptor to use for pharmacokinetic studies in the obese? , 2004, British journal of clinical pharmacology.

[58]  T. Pellis,et al.  The Effects of Cisatracurium on Morbidly Obese Women , 2004, Anesthesia and analgesia.

[59]  Carlos Iribarren,et al.  Body Mass Index and Risk for End-Stage Renal Disease , 2006, Annals of Internal Medicine.

[60]  C. Bernards,et al.  Respiratory and Sleep Effects of Remifentanil in Volunteers with Moderate Obstructive Sleep Apnea , 2009, Anesthesiology.

[61]  J. Bennett,et al.  Difficult or Impossible Ventilation after Sufentanil‐induced Anesthesia Is Caused Primarily by Vocal Cord Closure , 1997, Anesthesiology.

[62]  P. Metnitz,et al.  Impact of body mass on incidence and prognosis of acute kidney injury requiring renal replacement therapy , 2010, Intensive Care Medicine.

[63]  J. Levron,et al.  Performance of Target-controlled Sufentanil Infusion in Obese Patients , 2003, Anesthesiology.

[64]  R. Rondanelli,et al.  A Clinical and Pharmacokinetic Study , 1983 .

[65]  M. Avram,et al.  Using Front-end Kinetics to Optimize Target-controlled Drug Infusions , 2003, Anesthesiology.

[66]  J. O'Donnell,et al.  Desflurane versus sevoflurane for laparoscopic gastroplasty in morbidly obese patients. , 2007, Journal of clinical anesthesia.

[67]  R. Farinotti,et al.  Propofol Infusion for Maintenance of Anesthesia in Morbidly Obese Patients Receiving Nitrous Oxide A Clinical and Pharmacokinetic Study , 1993, Anesthesiology.

[68]  Russell D. Wada,et al.  Application of Physiologic Models to Predict the Influence of Changes in Body Composition and Blood Flows on the Pharmacokinetics of Fentanyl and Alfentanil in Patients , 1998, Anesthesiology.

[69]  A. J. Gandolfi,et al.  Weight, pseudocholinesterase activity, and succinylcholine requirement. , 1983, Anesthesiology.

[70]  E. Bignami,et al.  Randomized comparison of isoflurane and sevoflurane for laparoscopic gastric banding in morbidly obese patients. , 2001, Journal of clinical anesthesia.

[71]  P. Lindholm,et al.  Anthropometric Variables as Predictors for Duration of Action of Atracurium-Induced Neuromuscular Block , 1996, Anesthesia and analgesia.

[72]  S. Duffull,et al.  Caution when lean body weight is used as a size descriptor for obese subjects. , 2002, Clinical pharmacology and therapeutics.

[73]  J. McNeill,et al.  To scale or not to scale: the principles of dose extrapolation , 2009, British journal of pharmacology.

[74]  P. Lumb,et al.  Emergence and Recovery Characteristics of Desflurane Versus Sevoflurane in Morbidly Obese Adult Surgical Patients: A Prospective, Randomized Study , 2004, Anesthesia and analgesia.

[75]  A. Casati,et al.  Anesthesia in the obese patient: pharmacokinetic considerations. , 2005, Journal of clinical anesthesia.

[76]  D R Stanski,et al.  Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. , 1987, The Journal of pharmacology and experimental therapeutics.

[77]  L. Colla,et al.  Pharmacokinetic Model-Driven Remifentanil Administration in the Morbidly Obese , 2009, Clinical pharmacokinetics.

[78]  C. Guilleminault,et al.  Opioid medication and sleep-disordered breathing. , 2010, The Medical clinics of North America.

[79]  M. Struys,et al.  Optimization of desflurane administration in morbidly obese patients: a comparison with sevoflurane using an 'inhalation bolus' technique. , 2003, British journal of anaesthesia.

[80]  A. Artru,et al.  Long-Duration Low-Flow Sevoflurane and Isoflurane Effects on Postoperative Renal and Hepatic Function , 2001, Anesthesia and analgesia.

[81]  Mosteller Rd Simplified Calculation of Body-Surface Area , 1987 .

[82]  H. Shankar,et al.  Choice of volatile anesthetic for the morbidly obese patient: sevoflurane or desflurane. , 2005, Journal of clinical anesthesia.

[83]  B V Howard,et al.  Relations of Stroke Volume and Cardiac Output to Body Composition: The Strong Heart Study , 2001, Circulation.

[84]  R. Weiskopf,et al.  Kinetics of desflurane, isoflurane, and halothane in humans. , 1991, Anesthesiology.